Tag Archive for: Eir Ventures

Scrip Asks… What does 2023 hold for Biopharma?

More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Technological Advances Today’s article explores the technological advances expected during 2023. Developments in data science and molecular biology drive expectations – for another year of breakthrough innovation in human therapeutics. However, […]

What Next After A Year Of Innovation And Growth?

As part of its ‘Pharma Outlook for 2022’, leading healthcare publication, In Vivo, explored the outlook for US and EU venture capital funding in biopharma.  Asking whether the sector can keep the momentum going for investments, it drew on the experience and insight of prominent investors [many among them our clients,] to provide comment on […]